ERBB2 and cancer: The median (IQR) survival time from diagnosis of MBC was 19.3 (6.2-39.5) months in the overall cohort and 26.2 (14.5-42.8) months for HR-positive/ERBB2-negative cancer, 27.8 (13.3-44.3) months for ERBB2-positive/HR-positive cancer, 22.9 (8.1-42.6) months for ERBB2-positive/HR-negative cancer, 8.8 (3.5-17.5) months for TNBC, and 13.2 (4.2-37.4) months for unknown subtypes.